Charles Lassiter, MD
Pulmonary Disease · Marietta, GANPI 1386671998
Payments from drug & device makers
Across 221 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$868
- AstraZeneca$768
- Grifols USA, LLC$427
- Takeda Pharmaceuticals U.S.A., Inc.$249
- Insmed, Inc.$235
- Regeneron Healthcare Solutions, Inc.$233
- plus $1K from 27 others
What the payments were for
- Food & beverage$4,21099%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 62 | $868 |
| AstraZeneca | 38 | $768 |
| Grifols USA, LLC | 21 | $427 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $249 |
| Insmed, Inc. | 9 | $235 |
| Regeneron Healthcare Solutions, Inc. | 11 | $233 |
| Sanofi | 7 | $159 |
| Boehringer Ingelheim | 6 | $113 |
| Harmony Biosciences LLC | 3 | $111 |
| Pfizer | 6 | $100 |
| Philips North America LLC | 5 | $99 |
| Mylan Specialty L.p. | 5 | $91 |
| Octapharma USA, Inc. | 1 | $80 |
| Amgen | 4 | $71 |
| Jazz Pharmaceuticals Inc. | 3 | $63 |
| Axsome Therapeutics, Inc. | 3 | $62 |
| Verona Pharma, Inc. | 2 | $53 |
| Mallinckrodt Enterprises LLC | 2 | $49 |
| 3b Medical, Inc. | 1 | $47 |
| Actelion Pharmaceuticals US, Inc. | 2 | $44 |
| Mallinckrodt Hospital Products Inc. | 2 | $38 |
| Merck | 2 | $36 |
| Johnson & Johnson | 2 | $34 |
| CSL Behring | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| United Therapeutics Corporation | 1 | $27 |
| Resmed Corp | 2 | $25 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Viatris Specialty LLC | 1 | $21 |
| Covis Pharma GmbH | 1 | $16 |
| Abbott | 1 | $15 |
| Pulmonx Corporation | 1 | $13 |
| Novartis | 1 | $11 |
How this compares
$4,235 in reported general payments places this provider in the 45th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 402 | $510,548 |
| Breo ElliptaFluticasone/Vilanterol | 104 | $66,763 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 71 | $66,131 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 58 | $59,470 |
| EliquisApixaban | 60 | $54,142 |
| XareltoRivaroxaban | 15 | $20,327 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $17,072 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 444 | $11,937 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 17 | $11,270 |
| Arnuity ElliptaFluticasone Furoate | 22 | $8,004 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $7,295 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 13 | $5,581 |
| Azelastine Hcl | 120 | $4,890 |
| Ipratropium Bromide | 99 | $4,041 |
| Fluticasone Propionate | 202 | $3,167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $868 | $651,446599 claims |
| Boehringer IngelheimStiolto Respimat | $113 | $59,47058 claims |
| PfizerEliquis | $100 | $54,14260 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere | $768 | $22,65332 claims |
| Johnson & JohnsonXarelto | $34 | $20,32715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Marietta
- Hitendra PatelMarietta$104K
- Jeffrey MichaelsonMarietta$69K
- Amyn HiraniMarietta$68K
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.